Judith Pickett Fox

US Patent:

20010046496, Nov 29, 2001

Filed:

Dec 27, 2000

Appl. No.:

09/748960

Inventors:

Lee Brettman - Sudbury MA, US
Judith Fox - San Francisco CA, US
David Allison - Burlingame CA, US

International Classification:

A61K039/395

US Classification:

424/142100

Abstract:

Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for 47 integrin. Preferably, no more than about 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month.

US Patent:

20050095238, May 5, 2005

Filed:

Dec 15, 2003

Appl. No.:

10/735863

Inventors:

Lee Brettman - Sudbury MA, US
Judith Fox - San Francisco CA, US
David Allison - Burlingame CA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA
Genentech, Inc. - South San Francisco CA

International Classification:

A61K039/395

US Classification:

424141100, 424144100

Abstract:

Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for α4β7 integrin. Preferably, no more than about 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month.

US Patent:

20120034243, Feb 9, 2012

Filed:

Aug 5, 2011

Appl. No.:

13/204139

Inventors:

Lee R. Brettman - Sudbury MA, US
Judith A. Fox - San Francisco CA, US
David Edward Allison - Burlingame CA, US

International Classification:

A61K 39/395
A61P 1/04
A61P 1/00

US Classification:

4241731

Abstract:

Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for α4β7 integrin. Preferably, no more than 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month.